Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study

- Posted in Duchenne Expert Webinars, General, Research
Wave exon skipping Duchenne

Wave Life Science Exon Skipping in Duchenne


Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s exon skipping investigational therapy for Duchenne being investigated for individuals who are amenable to exon 53 skipping. We will share the recently announced 48-week FORWARD-53 data.

Watch the webinar HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate